Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients

There is a high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson’s disease (PD) patients, but a Chinese version of cognitive rating scale that is specific and sensitive to PD patients is still lacking. The aims of this study are to test the reliability and validity of a Chines...

Full description

Bibliographic Details
Main Authors: Yuyan Tan, Weiguo Liu, Juanjuan Du, Miaomiao Hou, Cuiyu Yu, Yang Liu, Shishuang Cui, Lei Yan, Yizhou Lu, Hong Lv, Lijun Han, Xi Wang, Shengyu Zha, Xiaoguang Luo, Huidong Tang, Shengdi Chen
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Parkinson's Disease
Online Access:http://dx.doi.org/10.1155/2020/5289136
id doaj-4b201b81c058483a9d4d36957b9f36a5
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yuyan Tan
Weiguo Liu
Juanjuan Du
Miaomiao Hou
Cuiyu Yu
Yang Liu
Shishuang Cui
Lei Yan
Yizhou Lu
Hong Lv
Lijun Han
Xi Wang
Shengyu Zha
Xiaoguang Luo
Huidong Tang
Shengdi Chen
spellingShingle Yuyan Tan
Weiguo Liu
Juanjuan Du
Miaomiao Hou
Cuiyu Yu
Yang Liu
Shishuang Cui
Lei Yan
Yizhou Lu
Hong Lv
Lijun Han
Xi Wang
Shengyu Zha
Xiaoguang Luo
Huidong Tang
Shengdi Chen
Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
Parkinson's Disease
author_facet Yuyan Tan
Weiguo Liu
Juanjuan Du
Miaomiao Hou
Cuiyu Yu
Yang Liu
Shishuang Cui
Lei Yan
Yizhou Lu
Hong Lv
Lijun Han
Xi Wang
Shengyu Zha
Xiaoguang Luo
Huidong Tang
Shengdi Chen
author_sort Yuyan Tan
title Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
title_short Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
title_full Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
title_fullStr Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
title_full_unstemmed Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
title_sort validation of revised chinese version of pd-crs in parkinson’s disease patients
publisher Hindawi Limited
series Parkinson's Disease
issn 2090-8083
2042-0080
publishDate 2020-01-01
description There is a high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson’s disease (PD) patients, but a Chinese version of cognitive rating scale that is specific and sensitive to PD patients is still lacking. The aims of this study are to test the reliability and validity of a Chinese version of Parkinson’s disease-cognitive rating scale (PD-CRS), establish cutoff scores for diagnosis of Parkinson’s disease dementia (PDD) and PD with mild cognitive impairment (PD-MCI), explore cognitive profiles of PD-MCI and PDD, and find cognitive deficits suggesting a transition from PD-MCI to PDD. PD-CRS was revised based on the culture background of Chinese people. Ninety-two PD patients were recruited in three PD centers and were classified into PD with normal cognitive function (PD-NC), PD-MCI, and PDD subgroups according to the cognitive rating scale (CDR). Those PD patients underwent PD-CRS blind assessment by a separate neurologist. The PD-CRS showed a high internal consistency (Cronbach’s Alpha = 0.840). Intraclass Correlation coefficient (ICC) of test-retest reliability reached 0.906 (95% CI 0.860–0.935, p<0.001). ICC of inter-rater reliability was 0.899 (95% CI 0.848–0.933, p<0.001). PD-CRS had fair concurrent validity with MDRS (ICC = 0.731, 95% CI 0.602–0.816). All the frontal-subcortical items showed significant decrease in PD-MCI compared with the PD-NC group (p≤0.001), but the instrument cortical items did not (confrontation naming p=0.717, copying a clock p=0.620). All the frontal-subcortical and instrumental-cortical functions showed significant decline in PDD compared with the PD-NC group (p≤0.001). The cutoff value for diagnosis of PD-MCI is 80.5 with the sensitivity of 75.7% and the specificity of 75.0%, and for diagnosis of PDD is 73.5 with the sensitivity of 89.2% and the specificity of 98.9%. Revised Chinese version of PD-CRS is a reliable, acceptable, valid, and useful neuropsychological battery for assessing cognition in PD patients.
url http://dx.doi.org/10.1155/2020/5289136
work_keys_str_mv AT yuyantan validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT weiguoliu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT juanjuandu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT miaomiaohou validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT cuiyuyu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT yangliu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT shishuangcui validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT leiyan validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT yizhoulu validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT honglv validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT lijunhan validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT xiwang validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT shengyuzha validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT xiaoguangluo validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT huidongtang validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
AT shengdichen validationofrevisedchineseversionofpdcrsinparkinsonsdiseasepatients
_version_ 1715776738844213248
spelling doaj-4b201b81c058483a9d4d36957b9f36a52020-11-25T01:24:55ZengHindawi LimitedParkinson's Disease2090-80832042-00802020-01-01202010.1155/2020/52891365289136Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease PatientsYuyan Tan0Weiguo Liu1Juanjuan Du2Miaomiao Hou3Cuiyu Yu4Yang Liu5Shishuang Cui6Lei Yan7Yizhou Lu8Hong Lv9Lijun Han10Xi Wang11Shengyu Zha12Xiaoguang Luo13Huidong Tang14Shengdi Chen15Department of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology, Ruijin Hospital North Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201800, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology, The First Affiliated Hospital of China Medical University, Shenyang 110001, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, The First Affiliated Hospital of China Medical University, Shenyang 110001, ChinaDepartment of Neurology, Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology, Shenzhen People’s Hospital, Second Clinical Medical College of Jinan University, Shenzhen 518020, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaThere is a high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson’s disease (PD) patients, but a Chinese version of cognitive rating scale that is specific and sensitive to PD patients is still lacking. The aims of this study are to test the reliability and validity of a Chinese version of Parkinson’s disease-cognitive rating scale (PD-CRS), establish cutoff scores for diagnosis of Parkinson’s disease dementia (PDD) and PD with mild cognitive impairment (PD-MCI), explore cognitive profiles of PD-MCI and PDD, and find cognitive deficits suggesting a transition from PD-MCI to PDD. PD-CRS was revised based on the culture background of Chinese people. Ninety-two PD patients were recruited in three PD centers and were classified into PD with normal cognitive function (PD-NC), PD-MCI, and PDD subgroups according to the cognitive rating scale (CDR). Those PD patients underwent PD-CRS blind assessment by a separate neurologist. The PD-CRS showed a high internal consistency (Cronbach’s Alpha = 0.840). Intraclass Correlation coefficient (ICC) of test-retest reliability reached 0.906 (95% CI 0.860–0.935, p<0.001). ICC of inter-rater reliability was 0.899 (95% CI 0.848–0.933, p<0.001). PD-CRS had fair concurrent validity with MDRS (ICC = 0.731, 95% CI 0.602–0.816). All the frontal-subcortical items showed significant decrease in PD-MCI compared with the PD-NC group (p≤0.001), but the instrument cortical items did not (confrontation naming p=0.717, copying a clock p=0.620). All the frontal-subcortical and instrumental-cortical functions showed significant decline in PDD compared with the PD-NC group (p≤0.001). The cutoff value for diagnosis of PD-MCI is 80.5 with the sensitivity of 75.7% and the specificity of 75.0%, and for diagnosis of PDD is 73.5 with the sensitivity of 89.2% and the specificity of 98.9%. Revised Chinese version of PD-CRS is a reliable, acceptable, valid, and useful neuropsychological battery for assessing cognition in PD patients.http://dx.doi.org/10.1155/2020/5289136